$ 199 / 10mg
999 in stock (can be backordered)
Survodutide is a dual-agonist research compound that simultaneously activates GLP-1 and glucagon receptors, studied for its role in metabolic regulation, appetite signaling, and energy-expenditure pathways. Survodutide peptide’s two-pathway mechanism distinguishes it from single-target GLP-1 compounds by adding glucagon-receptor-mediated thermogenesis and hepatic lipid mobilization — creating a more comprehensive metabolic research profile.
Survodutide peptide activates GLP-1 receptors to promote insulin secretion, reduce appetite, and slow gastric emptying. Simultaneously, it activates glucagon receptors to increase hepatic glucose production, stimulate lipolysis, and drive energy expenditure through thermogenesis. This dual activation creates opposing effects on glucose (GLP-1 lowers it, glucagon raises it) that researchers study for achieving metabolic balance — net weight reduction with maintained glucose control.
Mazdutide offers a closely related dual GLP-1/glucagon mechanism for head-to-head comparison. Retatrutide adds GIP-receptor activation for triple-agonist research. Cagrilintide targets amylin receptors for an alternative appetite-suppression pathway.
Each 10 mg vial contains Survodutide peptide manufactured in the USA under ISO-certified conditions. Verified to ≥99% purity by HPLC analysis, with endotoxin screening below 0.1 EU/mg. Certificate of Analysis (COA) available upon request. For laboratory research use only.
Lyophilized Survodutide peptide should be stored at -20°C in a sealed container protected from moisture and light for maximum long-term stability. Upon reconstitution with bacteriostatic water, the solution should be stored at 2–8°C and used within 28 days. Avoid repeated freeze-thaw cycles by preparing single-use aliquots at the time of reconstitution. All handling should follow standard laboratory peptide protocols. This product is intended for research use only and is not for human consumption.
Survodutide (formerly BI 456906) was developed by Boehringer Ingelheim as a dual GLP-1/glucagon receptor agonist and entered preclinical evaluation in the mid-2010s. The compound advanced through multiple clinical-stage studies examining metabolic endpoints including body weight, hepatic fat content, and glycemic control. Published research on dual GLP-1/glucagon agonism spans over 150 peer-reviewed articles across journals such as The Lancet, Diabetes Care, and Cell Metabolism. Academic institutions including the Helmholtz Zentrum München and the German Center for Diabetes Research have contributed significantly to understanding the pharmacology of dual-incretin receptor targeting. Survodutide represents an important research tool for investigating how simultaneous GLP-1 and glucagon activation produces distinct metabolic outcomes compared to single-receptor agonists.
AgeFix Survodutide is verified to ≥99% purity by HPLC analysis and undergoes endotoxin screening to confirm levels below 0.1 EU/mg. Each 10 mg vial is manufactured in the USA under ISO-certified conditions, with a Certificate of Analysis (COA) available upon request.
Survodutide activates two receptors (GLP-1 and glucagon), while Retatrutide activates three (GLP-1, GIP, and glucagon). This makes Survodutide valuable for isolating the specific contributions of dual GLP-1/glucagon signaling without GIP-receptor confounding, enabling cleaner receptor-pathway analysis in metabolic research models.
Lyophilized Survodutide should be stored at -20°C for long-term stability. After reconstitution with bacteriostatic water, store at 2–8°C and use within 28 days. This product is sold for laboratory research use only and is not intended for human consumption.
